Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report (Q26825405)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

review article

1 reference

title

Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report (English)

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

3 March 2020

main subject

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

4

Shelby D Reed

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1

Scott D Ramsey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Henry Glick

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Federico Augustovski

5

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Bengt Jonsson

6

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Richard J Willke

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sean D Sullivan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

1 reference

1 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

18

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

2

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

161-172

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Analysis of cost data in randomized trials: an application of the non-parametric bootstrap

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Fieller's method and net health benefits

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Comparison of self administered survey questionnaire responses collected using mobile apps versus other methods

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Whither trial-based economic evaluation for health care decision making?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Expected value of information and decision making in HTA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Cost-minimisation analysis versus cost-effectiveness analysis, revisited.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Costs, effects and C/E-ratios alongside a clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The death of cost-minimization analysis?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Representing uncertainty: the role of cost-effectiveness acceptability curves

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Missing... presumed at random: cost-analysis of incomplete data

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Comparing costing results in across country economic evaluations: the use of technology specific purchasing power parities.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

An economic approach to clinical trial design and research priority-setting

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Sample size calculation in economic evaluations

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Estimating country-specific cost-effectiveness from multinational clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Resource costing for multinational neurologic clinical trials: methods and results.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Assessing the appropriateness of combining economic data from multinational clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Choice of test for comparing two groups, with particular application to skewed outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The value of information and optimal clinical trial design.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Cost-effectiveness analysis for multinational clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Incremental net benefit in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Relative effectiveness and the European pharmaceutical market

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Validity and reliability of the Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The road not taken: transferability issues in multinational trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Estimating productivity costs in health economic evaluations: a review of instruments and psychometric evidence

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Explanatory and pragmatic attitudes in therapeutical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Conversion factor instability in international comparisons of health care expenditure

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

On estimators of medical costs with censored data

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Estimating medical care costs under conditions of censoring

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Using a discrete choice experiment to estimate health state utility values.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Development of a database of instruments for resource-use measurement: purpose, feasibility, and design

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Should linking replace regression when mapping from profile-based measures to preference-based measures?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Improving the contribution of regulatory assessment reports to health technology assessments--a collaboration between the European Medicines Agency and the European network for Health Technology Assessment

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Economic analysis of lung volume reduction surgery as part of the National Emphysema Treatment Trial. NETT Research Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Estimating log models: to transform or not to transform?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The estimation of a preference-based measure of health from the SF-36.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The structure of demand for health care: latent class versus two-part models

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Accounting for future costs in medical cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The logged dependent variable, heteroscedasticity, and the retransformation problem.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Modeling risk using generalized linear models

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

On the use of survival analysis techniques to estimate medical care costs

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Analysis of costs and cost-effectiveness in multinational trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Medicare's DRG-weights in a European environment: the Spanish experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

1 reference

7 January 2021

Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

A note on confidence intervals in cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

A comparison of methods for analyzing health-related quality-of-life measures.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The randomized registry trial--the next disruptive technology in clinical research?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

A regression-based method for estimating mean treatment cost in the presence of right-censoring

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Estimating marginal and incremental effects on health outcomes using flexible link and variance function models

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Mapping for economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Acute myocardial infarction and diagnosis-related groups: patient classification and hospital reimbursement in 11 European countries

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Mode of questionnaire administration can have serious effects on data quality

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Modeling valuations for EuroQol health states

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The Work Limitations Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Multiattribute and single-attribute utility functions for the health utilities index mark 3 system

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Median regression with censored cost data

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Are N-of-1 trials an economically viable option to improve access to selected high cost medications? The Australian experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

1 reference

7 January 2021

Transformations, means, and confidence intervals

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The use of transformation when comparing two means

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Analysis and interpretation of cost data in randomised controlled trials: review of published studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

How should cost data in pragmatic randomised trials be analysed?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Economics notes: Converting international cost effectiveness data to UK prices

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

An updated coronary risk profile. A statement for health professionals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Expected value of sample information calculations in medical decision modeling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Exploring the Research Decision Space: The Expected Value of Information for Sequential Research Designs

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

US valuation of the SF-6D.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Valuing SF-6D Health States Using a Discrete Choice Experiment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Underestimation of uncertainties in health utilities derived from mapping algorithms involving health-related quality-of-life measures: statistical explanations and potential remedies

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Carrier screening for cystic fibrosis: costs and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Power and sample size in cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Self-reported utilization of health care services: improving measurement and accuracy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The distribution of health care costs and their statistical analysis for economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Optimal sample size determinations from an industry perspective based on the expected value of information

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Country-specific cost-effectiveness of early intervention with budesonide in mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Pre-test of questions on health-related resource use and expenditure, using behaviour coding and cognitive interviewing techniques

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Multiple imputation: a primer

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Multiple Imputation in Practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Application of multi-attribute utility theory to measure social preferences for health states

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Four health data networks illustrate the potential for a shared national multipurpose big-data network

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The validity and reproducibility of a work productivity and activity impairment instrument

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

An Analysis of NICEʼs ‘Restricted’ (or ‘Optimized’) Decisions

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Principles for planning and conducting comparative effectiveness research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Estimating a treatment effect from multidimensional longitudinal data

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Estimating medical costs from incomplete follow-up data

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

Design of a national distributed health data network

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JVAL.2015.02.001

7 January 2021

10.1016/J.JVAL.2015.02.001

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25773551%20AND%20SRC:MED&resulttype=core&format=json

release_6c3l4zmtcvfkdbyh6mfeqqub3m

3 March 2020

Fatcat ID

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017